Experimental IDH drug trial halted early

NCT ID NCT04762602

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 33 times

Summary

This early-stage study tested an experimental drug called HMPL-306 in people with advanced solid tumors that have a specific genetic change (IDH mutation). The main goals were to find a safe dose and check for side effects. The study was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISOCITRATE DEHYDROGENASE GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Emory University

    Atlanta, Georgia, 30322, United States

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital de la Santa creu i Sant Pau

    Barcelona, 08025, Spain

  • Houston Methodist

    Houston, Texas, 77030, United States

  • Sarcoma Oncology Research Center

    Santa Monica, California, 90403, United States

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

  • UPMC Hillman Cancer

    Pittsburgh, Pennsylvania, 15232, United States

  • University of Iowa

    Iowa City, Iowa, 52242, United States

  • University of Kentucky

    Lexington, Kentucky, 40536, United States

Conditions

Explore the condition pages connected to this study.